

Decitabine for Myelodysplastic Syndrome: Inpatient regimen

Contact Physician: _____ **Pager:** _____

Diagnosis: _____

Cycle: _____ **Day 1 =** _____ **Cycle 1: consent form done**

Weight: _____ **Height:** _____ **BSA:** _____

Adjusted IBW: _____ **Adjusted BSA:** _____

Allergies: _____

Decitabine 15 mg/m² IV over three hours every 8 hours times 3 days (inpatient regimen). May repeat every 6 weeks.

1. Hydration:

2. Prophylactic medications:

- Allopurinol: 300mg PO daily for _____ days
- Acyclovir: 400mg PO twice daily
- Antifungal:
- GI prophylaxis:

3. Anti-emetics: Moderate emetogenic potential

- Ondansetron 12 mg PO every 8 hours prior to each dose of decitabine
- Lorazepam: 0.5mg - 1 mg PO or IV every 4 hours prn nausea
- Prochlorperazine 10mg PO or IV every 6 hours prn nausea

4. Chemotherapy: INPATIENT

- Decitabine** (15mg/m²) _____mg in Sodium Chloride 0.9% 100mL IV over 3 hours every 8 hours times 3 days (total 9 doses).

Decitabine _____mg IV over 3 hours dose 1
Decitabine _____mg IV over 3 hours dose 2
Decitabine _____mg IV over 3 hours dose 3
Decitabine _____mg IV over 3 hours dose 4
Decitabine _____mg IV over 3 hours dose 5
Decitabine _____mg IV over 3 hours dose 6
Decitabine _____mg IV over 3 hours dose 7
Decitabine _____mg IV over 3 hours dose 8
Decitabine _____mg IV over 3 hours dose 9

Signed: _____ Pager: _____

BJ Hematology 114, 2001: 349-357 and Cancer 106(8) 2006: 1794-1803
(inpatient regimen)

Blood 109 (1) 2007: 52-57. (outpatient regimen).

Recommended dose reductions:

Decrease dose by 25-30% rounded to 10, 7.5 and 5mg/m² for grade 3-4 non-myelosuppressive toxicities, for severe myelosuppression-associated complications (infection, bleeding), or for prolonged myelosuppression (6 weeks or longer) without evidence of disease.

Consider 50% dose reductions for severe complications, if judged in the best safety interest of the patient.

Filgrastim may be given in the setting of neutropenic fever or infection; or in a patient in CR but with prolonged neutropenia prior to next course of decitabine.